fda approval bpc-157 status RFK Jr pushes for of peptide | Eric Topol, MD posted on the topic BPC-157 Before the FDA: Briefing
Description
Its effectiveness isnt just about the vitaminits also about where its injected
These MVs carry not only CD38, but also CD39, CD73 and CD203a ectoenzymes, inhibitory complement receptors CD55 and CD59, the checkpoint inhibitor PD-L1, and the myeloma differentiation marker CD138 ( In addition to reducing surface CD38, antibody-induced modulation may involve two other mechanisms: i) signal transduction that activates intracellular signaling pathways, and ii) cargo transfer
Site rotation prevents local tissue irritation from repeated injections
10.1097/MPG.0000000000001310 38 HanssonG
